Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Parallel-arm, Phase I Study to Evaluate the Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab (MabThera) Induction Immunotherapy as a First-line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Conditions
Interventions
BI 695500
MabThera
Locations
29
Australia
The Canberra Hospital
Canberra, Migration Data, Australia
AKH - Medical University of Vienna
Vienna, Austria
Brussels - UNIV St-Luc
Brussels, Belgium
UZ Leuven
Leuven, Belgium
Namur - HOSP Ste-Elisabeth
Namur, Belgium
Clinical Hospital Centre Zagreb
Zagreb, Croatia
Start Date
September 27, 2013
Primary Completion Date
December 22, 2015
Completion Date
December 22, 2015
Last Updated
September 5, 2018
NCT06785818
NCT04911478
NCT06425302
NCT02278796
NCT00081809
NCT02376699
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions